Biotie's nepicastat misses PTSD endpoint

Biotie Therapies Corp. (HSE:BTH1V) said nepicastat missed the primary endpoint of improving post-traumatic stress disorder (PTSD)-associated symptoms at week six vs. placebo in a Phase II trial. Bioti...